Quick test for detecting dengue virus infections
Official title: Rapid Point-of-Care RNA Diagnostic for Dengue Infection
Funded at Crosslife Technologies, INC. · NIH-10469689 · Data updated 2026-11-12
This study is working on a quick and easy test for dengue virus that can give results in just 30 minutes using a simple paper strip, making it perfect for people in tropical areas who need fast answers without complicated lab equipment.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Crosslife Technologies, INC. NIH-funded |
| Lab location | 1 site (Carlsbad, United States) |
| Project start | March 15, 2019 |
| Project end | July 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $999,799 |
| NIH project number | 5R44AI140813-03 |
| Project ID | NIH-10469689 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing symptoms of dengue fever, particularly in endemic regions of Southeast Asia and Latin America.
✕Less likely to help
Patients who are not in areas where dengue is endemic or those who do not exhibit symptoms of dengue infection may not benefit from this research.
What this research studies
This research focuses on developing a rapid point-of-care diagnostic test for dengue virus infections, which are prevalent in tropical regions. The test aims to provide results within 30 minutes using a simple paper strip, allowing for immediate treatment decisions. By utilizing a novel Template Assisted Rapid Assay (TARA) technology, the diagnostic can detect the virus directly from whole blood samples without the need for complex laboratory equipment. This approach is particularly beneficial in areas where traditional testing methods are unavailable or too slow.
Why it matters
Potential benefit: If successful, this research could lead to faster diagnosis and treatment of dengue infections, potentially saving lives and reducing the spread of the virus.
How similar studies have gone: Other research has shown promise in developing rapid diagnostic tests for infectious diseases, indicating that this approach could be effective for dengue as well.
Where this research is happening
-
Crosslife Technologies, INC.
Carlsbad, United States Active
Researchers
- Principal investigator: Cho, Hyundae — Crosslife Technologies, INC.
- Study coordinator: Cho, Hyundae
Related research
Other NIH-funded projects on the same topics.
-
Immune responses linked to severe dengue in children (primary infection)
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
-
Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Defining immune markers predicting protection against dengue in a long-term family study in Thailand
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
-
Understanding dengue protection in children from a long-term Thai family cohort
A long-term study in Thailand follows families to understand how early exposures to dengue shape protection and illness risk for children as they encounter the virus over time.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.